On November 7, 2022 Cytovia Therapeutics, Inc., a biopharmaceutical company empowering natural killer (NK) cells to fight cancer through stem cell engineering and bispecific antibodies, reported new preclinical data for its TALEN gene-edited, iPSC-derived NK (iNK) cells and GPC3-targeted Flex-NK bispecific antibodies (Press release, Cytovia Therapeutics, NOV 7, 2022, View Source [SID1234623320]). The data will be presented at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 37th Annual Meeting (SITC 2022) taking place in Boston, MA, and virtually November 8-12th, 2022.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We’re delighted to see further progress on our lead GPC3-targeted Flex-NK bispecific antibody program, with a pre-clinical package that supports clinical evaluation in 2023," commented Cytovia CEO Dr. Daniel Teper. "Additionally, we have now generated TALEN gene-edited iNK cells and demonstrated enhanced antitumor activity. Cytovia is the first company to develop both its own immune cell engagers and natural killer cells, with the potential for enhanced efficacy in cancers with significant unmet medical needs such as Hepatocellular Carcinoma."
The presentations show that Cytovia’s allogeneic iNK cell product CYT-100 demonstrated increased time-dependent killing of Hep3B tumor spheroids and sensitivity to cytokine activation & expansion potential. Cytovia’s GPC3-targeted bispecific antibody CYT-303 demonstrated potent ADCP and CDC against Hep3B tumors as well as Hep3B tumor spheroid and serial killing activities in the presence Cytovia’s allogeneic iNK cell product CYT-100 and PBNKs in a dose-dependent manner. Preclinical pharmacokinetics and safety study results in monkeys fully support CYT-303 clinical development.
Cytovia’s next-generation iNK cell platform combined with TALEN gene-editing robustly and reliably generated single-cell edited iPSC clones, which were expanded and differentiated into functionally improved iNK cells. The data shows that iNK cells edited with an IL-15 knock-in and TGFβR2 knock-out result in enhanced antitumor activity. The editing and manufacturing process will enable clinical evaluation of these product candidates, both alone in combination with CYT-303.